1. Home
  2. DGICB vs PHAR Comparison

DGICB vs PHAR Comparison

Compare DGICB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICB

Donegal Group Inc. Class B

N/A

Current Price

$24.49

Market Cap

889.2M

Sector

Finance

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$12.40

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICB
PHAR
Founded
1986
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.2M
1.0B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
DGICB
PHAR
Price
$24.49
$12.40
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$38.33
AVG Volume (30 Days)
10.0K
15.4K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$978,014,322.00
N/A
Revenue This Year
$2.26
$10.04
Revenue Next Year
N/A
$2.51
P/E Ratio
$8.06
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$14.02
$9.62
52 Week High
$29.99
$21.34

Technical Indicators

Market Signals
Indicator
DGICB
PHAR
Relative Strength Index (RSI) 53.79 51.77
Support Level $15.24 $12.08
Resistance Level $24.20 $13.61
Average True Range (ATR) 1.05 0.68
MACD 0.04 0.14
Stochastic Oscillator 73.98 71.08

Price Performance

Historical Comparison
DGICB
PHAR

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: